- Home
- WALD vs CRVS Comparison
WALD vs CRVS Comparison
Compare WALD & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WALD
- CRVS
- Stock Information
- Founded
- WALD 1988
- CRVS 2014
- Country
- WALD United States
- CRVS United States
- Employees
- WALD N/A
- CRVS N/A
- Industry
- WALD Package Goods/Cosmetics
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- WALD Consumer Discretionary
- CRVS Health Care
- Exchange
- WALD Nasdaq
- CRVS Nasdaq
- Market Cap
- WALD 306.3M
- CRVS 305.4M
- IPO Year
- WALD 2021
- CRVS 2016
- Fundamental
- Price
- WALD $1.56
- CRVS $5.75
- Analyst Decision
- WALD Strong Buy
- CRVS Strong Buy
- Analyst Count
- WALD 5
- CRVS 4
- Target Price
- WALD $4.96
- CRVS $15.00
- AVG Volume (30 Days)
- WALD 528.0K
- CRVS 518.7K
- Earning Date
- WALD 11-11-2025
- CRVS 08-07-2025
- Dividend Yield
- WALD N/A
- CRVS N/A
- EPS Growth
- WALD N/A
- CRVS N/A
- EPS
- WALD N/A
- CRVS N/A
- Revenue
- WALD $273,868,000.00
- CRVS N/A
- Revenue This Year
- WALD $10.37
- CRVS N/A
- Revenue Next Year
- WALD $14.37
- CRVS N/A
- P/E Ratio
- WALD N/A
- CRVS N/A
- Revenue Growth
- WALD 25.55
- CRVS N/A
- 52 Week Low
- WALD $1.50
- CRVS $2.54
- 52 Week High
- WALD $4.40
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- WALD 35.98
- CRVS 65.10
- Support Level
- WALD $1.50
- CRVS $5.28
- Resistance Level
- WALD $1.79
- CRVS $5.64
- Average True Range (ATR)
- WALD 0.16
- CRVS 0.30
- MACD
- WALD 0.00
- CRVS 0.03
- Stochastic Oscillator
- WALD 10.00
- CRVS 77.70
About WALD Waldencast plc
Waldencast PLC is a beauty and wellness operating platform. The company is organized into two reportable segments namely Obagi Skincare and Milk Makeup. The company generates the majority of its revenue from the Obagi Medical segment. The Obagi Medical segment is engaged in developing, marketing, and selling skin health products. The Milk Makeup segment includes developing, marketing, and selling cosmetics, skincare, and other beauty products. Geographically the company generates the majority of its revenue from North America region.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).